Biosimilars unlikely to be commercialized within 2 or 3 years

Published: 2009-10-28 06:59:00

Updated: 2009-10-28 06:59:00

The government will need to proceed with biosimilar projects with more caution as the availability of second generation biologic products that offer superior dosing and/or therapeutic efficacy to the original reference brand is something of a double-edged sword for first generation biosimilars, a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK